Investor Presentaiton
HANSIZHUANG (Serplulimab): First Approved PD-1 mAb for 1L SCLC
Henlius
斯鲁利单抗注
艾斯状
100mg (10ml)/
1.12B RMB
Revenue in 2023
Henlius
斯鲁利单抗注射液
汉斯状 Ⓡ Ф
100mg (10ml)/ 01瓶/盒
ZerpidioⓇ in Indonesia
12
R
•
Widespread recognition
MAA for 1L ES-SCLC indication is under EMA review
Recommended in 2023 CSCO treatment guidelines for
SCLC, NSCLC, EC etc.
1L ESCC indication was approved in China in
September 2023
00 Differentiated strategies to seize the
market
Developed differentiated marketing strategies and
focused on SCLC to rapidly increase market share
and gain customer trust
Working with business partners to create more
commercial value and expand overseas market
Zerpidio
SERPLULIMAB
100 mg/10 mL
Solution for Infusion
For IV Use Only
NVU
Якаве
•
Efforts to product accessibility
Launched patient assistance programs to reduce
patients' economic burdens, to improve adherence so as
to optimize treatment outcomes
Covered by Huiminbao (Regional Commercial Health
Insurance) in 75 provinces/cities incl. Shanghai, Fujian,
Shaanxi, Chongqing, Nanjing, Suzhou, Chengdu, Jinan,
Xiamen etc. and greatly improve local residents' access
of HANSIZHUANGⓇ
Ⓒ Target: PD-1
Indications:
•
•
Acceleration on market access and
penetration
Completed tendering and procurement platform listing
in all provinces in China
~580 people commercial team with strong sales
experience in oncology and territories allocated
Established efficient distribution network, strengthening
the coverage of DTP pharmacies and infusion centers
to maximize patients' accessibility
Drug Specifications:
Zerpidio
SERPLULIMAB
Des. Incikas, dau informa
100 mg/ml
ebih ljut
hatcow
Thapa (10 mil manganding
Smash Bas
12--
Jared Na
and
HARUS DENGAN RESEP DOKTER
Dauradited-
Dampen clus
Dobley Lo
TOPAD but
Cialis
2024 Henlius.
•
MSI-H solid tumor
•
sqNSCLC
•
ES-SCLC
•
ESCC
100mg/10ml/bottle
2 HenliusView entire presentation